SCHEMBL1594419

SCHEMBL1594419

CCOC(=O)c1nc([N+](=O)[O-])cn1C

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MITF O75030 1/20 0.52
ALDH1A1 P00352 3/20 0.45
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 5/20 0.41
KCNJ1 P48048 1/20 0.41
KCNH2 Q12809 1/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
AR P10275 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5741754 0.99 MITF (0.51) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL1594228 0.84 ALDH1A1 (0.59) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL5313447 0.83 MITF (0.40) MITFALDH1A1L3MBTL1MAPTPOLB
SCHEMBL1080487 0.81 MITF (0.54) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL30211422 0.80 MITF (0.56) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL31614495 0.79 MITF (0.52) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL2028204 0.78 CYP1A2 (0.44) ALDH1A1MAPTPOLBKMT2AGAA
SCHEMBL3287960 0.78 ALDH1A1 (0.41) MITFALDH1A1L3MBTL1LMNAKMT2A
SCHEMBL1594872 0.78 MITF (0.51) MITFALDH1A1PTGS1PTGS2HTT
SCHEMBL31614485 0.78 MITF (0.48) MITFALDH1A1PTGS1PTGS2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120238-B Preparation method of imidazole derivative 山东梅奥华卫科技有限公司 2023-09-22 CN claimed
CN-116120238-A Preparation method of imidazole derivative 山东梅奥华卫科技有限公司 2023-05-16 CN claimed
US-20250368628-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES DESIGN THERAPEUTICS INC (US) 2025-12-04 US disclosed
US-20250295632-A1 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. 2025-09-25 US disclosed
EP-4539839-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES Design Therapeutics, Inc. (US) 2025-04-23 EP disclosed
EP-4539842-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES Design Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2025076181-A1 METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE Design Therapeutics, Inc. (US) 2025-04-10 WO disclosed
US-20250109132-A1 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA DESIGN THERAPEUTICS INC (US) 2025-04-03 US disclosed
CN-119677513-A Methods and compounds for modulating genetic disease 设计治疗公司 2025-03-21 CN disclosed
EP-4522168-A1 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2025-03-19 EP disclosed
EP-4460302-A2 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2024-11-13 EP disclosed
WO-2001088160-A2 VECTORS FOR DNA DELIVERY ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI, S.P.A. (IT) 2001-11-22 WO disclosed
US-6303312-B1 MODIFYING CELL PHENOTYPE; MEDICAL RESEARCH AND THERAPY CALIFORNIA INSTITUTE OF TECHNOLOGY 2001-10-16 US disclosed
US-6143901-A FORMINGA SPECIFIC COMPLEX BETWEEN A TARGET SEQUENCE OF DOUBLE STRANDED DNA AND AN OLIGOMER OR POLYMER OF N-METHYLPYRROLE CARBOXAMIDE AND N-METHYLIMIDAZOLE CARBOXAMID WHEREIN N-HETEROCYLCES ARE CONNCETED WITH AN AMINO ACID LINKING GROUP GENESOFT, INC. (US) 2000-11-07 US disclosed
US-6090947-A Method for the synthesis of pyrrole and imidazole carboxamides on a solid support CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-07-18 US disclosed
EP-0991417-A1 COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-04-12 EP disclosed
EP-0986539-A1 DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2000-03-22 EP disclosed
US-5998140-A COMPLEXES OF CELL WITH OLIGOMER THE SCRIPPS RESEARCH INSTITUTE (US) 1999-12-07 US disclosed
WO-1998050058-A1 COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1998-11-12 WO disclosed
WO-1998049142-A1 DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368628-A1 METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES CLN6, GATAD2B, MITF MITF 3/4885ALDH1A1 4027/4885PTGS1 3394/4885
US-20250295632-A1 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA ATXN2, CLN6, ATXN2L MITF 753/4885ALDH1A1 3096/4885PTGS1 3037/4885
US-20250109132-A1 COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA ATXN2, ATXN2L, ATXN10 MITF 183/4885ALDH1A1 4371/4885PTGS1 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.